Showing results (131-140 of 149) with videos related to

Sort By:
Pageof 15
Nephron|September 16, 1998
Plasma soluble fas and soluble fas ligand in chronic glomerulonephritisH Sano, K Asano, S Minatoguchi, et al.
Journal of Gastroenterology|April 16, 1999
Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon alphaM Kobayashi, K Chayama, Y Arase, et al.
Journal of Medical Virology|August 14, 1999
Fluctuations of hepatitis C virus load are not related to amino acid substitutions in hypervariable region 1 and interferon sensitivity determining regionM Hashimoto, K Chayama, M Kobayashi, et al.
Journal of the American College of Cardiology|May 1, 1997
Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failureK Nishigaki, S Minatoguchi, M Seishima, et al.
Journal of Gastroenterology and Hepatology|April 20, 1999
Prevalence of TT virus before and after blood transfusion in patients with chronic liver disease treated surgically for hepatocellular carcinomaM Kobayashi, K Chayama, Y Arase, et al.
Journal of Gastroenterology|November 4, 2000
Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearanceM Kobyashi, K Chayama, Y Arase, et al.
Journal of Viral Hepatitis|February 7, 2013
Virological response and safety of 24-week telaprevir alone in Japanese patients infected with hepatitis C virus subtype 1bJ Toyota, I Ozeki, Y Karino, et al.
Journal of Gastroenterology and Hepatology|June 26, 1998
Predictive factors in eradicating hepatitis C virus using a relatively small dose of interferonM Fukuda, K Chayama, A Tsubota, et al.
Scandinavian Journal of Gastroenterology|March 3, 2004
Wild-type precore and core promoter sequences in patients with acute self-limited or chronic hepatitis BM Kobayashi, Y Arase, K Ikeda, et al.
Hepatology (Baltimore, Md.)|June 10, 1998
Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapyK Chayama, Y Suzuki, M Kobayashi, et al.
Pageof 15